Ohio State University Comprehensive Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Ohio State University Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#105 of 15,742 sponsors by registered trial count).

341 total trials 77 currently recruiting 206 completed early-phase tilt top decile by trial count

Ohio State University Comprehensive Cancer Center: 341 sponsored US clinical trials, 77 recruiting.

Ohio State University Comprehensive Cancer Center sponsors 341 registered US clinical trials on ClinicalTrials.gov, 77 of them currently recruiting, and 206 completed. 5 of these trials are in Phase 3-4 (later-stage) and 116 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anatomic Stage II Breast Cancer AJCC v8, with 10 trials.

Top-decile sponsor footprint

Ohio State University Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#105 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 77/100

206 of 217 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

341 total, page 2 of 7

RECRUITING NA

Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer

NCT05984888

RECRUITING

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

NCT05178498

RECRUITING NA

Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial

NCT06314672

RECRUITING NA

Weighted Blanket Use to Reduce Anxiety in Oncology Patients

NCT06089408

RECRUITING NA

Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study

NCT05961982

RECRUITING NA

Head and Neck Cancer Patient Symptom and Oncologic Outcomes

NCT05243069

RECRUITING NA

Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)

NCT05178472

RECRUITING Early Phase 1

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

NCT05417308

RECRUITING NA

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

NCT05677802

RECRUITING Phase 2

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

NCT05336812

RECRUITING Early Phase 1

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

NCT05415709

RECRUITING Phase 1

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

NCT04754321

RECRUITING Phase 1

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

NCT04780568

RECRUITING Phase 1

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

NCT05136846

RECRUITING Phase 1

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

NCT04049539

RECRUITING Phase 2

Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise

NCT04427566

RECRUITING NA

Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer

NCT03711890

RECRUITING

Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions

NCT03492151

RECRUITING NA

Smoking Cessation Intervention Development for Homeless Youth

NCT06754215

RECRUITING NA

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

NCT03199651

RECRUITING

An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry

NCT02677961

RECRUITING

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

NCT02090530

RECRUITING

A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma

NCT04567706

RECRUITING

Hairy Cell Leukemia Patient Data Registry

NCT02560883

RECRUITING

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

NCT01408225

RECRUITING

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

NCT04022616

RECRUITING NA

Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

NCT01473784

ACTIVE NOT RECRUITING NA

A Dietary Intervention (Soy Soft Pretzels) for Reducing Chronic Inflammation in Obese Individuals

NCT07650409

ACTIVE NOT RECRUITING NA

Nicotine and Tobacco Message Framing to Change Smoking Behavior in Diverse Groups of Young Adult Smokers

NCT06644664

ACTIVE NOT RECRUITING NA

Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study

NCT06305884

ACTIVE NOT RECRUITING NA

Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial

NCT06445192

ACTIVE NOT RECRUITING NA

Respiratory Effects of E-Cigarettes in Obese Youth

NCT05869318

ACTIVE NOT RECRUITING Early Phase 1

Bioavailability and Pharmacodynamics of EPA and DHA From Fortified Soymilk and Capsules

NCT05802797

ACTIVE NOT RECRUITING Phase 2

Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases

NCT05503251

ACTIVE NOT RECRUITING NA

Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer

NCT05325151

ACTIVE NOT RECRUITING NA

A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer

NCT05215769

ACTIVE NOT RECRUITING

Impact of E-cigarette Use on the Body

NCT04972513

ACTIVE NOT RECRUITING NA

Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors

NCT04906200

ACTIVE NOT RECRUITING NA

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

NCT05972577

ACTIVE NOT RECRUITING

Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy

NCT05717998

ACTIVE NOT RECRUITING

Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy

NCT04713618

ACTIVE NOT RECRUITING NA

Effectiveness of a Multi-Level Smoking Cessation Program for High-Risk Women in Rural Communities

NCT04340531

ACTIVE NOT RECRUITING NA

Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM)

NCT04537312

ACTIVE NOT RECRUITING NA

I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination

NCT04452526

ACTIVE NOT RECRUITING

A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors

NCT06630429

ACTIVE NOT RECRUITING NA

Endobronchial Ultrasound-Guided Transbronchial Needle-Aspiration With Suction in Obtaining Samples From Patients With Suspected Nodal Metastatic Lung Cancer

NCT04116970

ACTIVE NOT RECRUITING Phase 2

Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia

NCT04466683

ACTIVE NOT RECRUITING NA

High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant

NCT03719092

ACTIVE NOT RECRUITING Phase 2

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

NCT03513562

ACTIVE NOT RECRUITING Phase 1

Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

NCT03824327

← Previous Page 2 of 7 Next →

What is open in the Ohio State University Comprehensive Cancer Center pipeline

77 recruiting of 341 indexed (23% open); 206 completed (60%).

Phase mix: 5 late (III/IV) vs 116 early (I/II) (early-phase heavy).

Top condition: Anatomic Stage II Breast Cancer AJCC v8 (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Ohio State University Comprehensive Cancer Center: open-pipeline peers nationwide

Peers matched on 341 registered trials and 23% open enrollment, not the therapeutic-area sidebar.

Ohio State University Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 5%10%15%20%25% Total trials Recruiting share Ohio State University Comprehensive Cancer CenterChildren's Oncology GroupNational Institute of Mental Health (NIMH)Cedars-Sinai Medical CenterNational Institutes of Health Clinical Center (CC)University of DelawareUniversity of VirginiaUniversity of Kansas Medical CenterUniversity of Oklahoma
Ohio State University Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ohio State University Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 341 trials (± recruiting share)

Sponsors near 23% open enrollment (± trial volume)

What to do with this Ohio State University Comprehensive Cancer Center page

341 registered trials is a research-attention snapshot, not an endorsement of Ohio State University Comprehensive Cancer Center or any single study.

  • 77 of Ohio State University Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Anatomic Stage II Breast Cancer AJCC v8 is the condition Ohio State University Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anatomic Stage II Breast Cancer AJCC v8 trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ohio State University Comprehensive Cancer Center pipeline card: 341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.